CTI BioPharma Profit Margin

CTI BioPharma (CTIC) currently reports a profit margin of -102.43% as of March 2023. That compares with -5133.64% in the prior-year period — up 98.0% year over year. That is below the Healthcare sector average of 17.63%. Use the charts on this page to explore CTI BioPharma's profit margin history and peer comparisons.

CTI BioPharma's profit margin increased from -5133.64% to -102.43% — a 98.0% year-over-year increase (period ending March 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

CTI BioPharma's profit margin of -102.43% is lower than the Healthcare sector average of 17.63%. That is roughly 681.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but CTI BioPharma's current -102.43% should be judged against Healthcare norms (sector average: 17.63%) and against CTIC's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -102.43%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 17.63%. From there, open related valuation or income-statement pages for CTI BioPharma, and consider following CTIC for alerts when major investors trade the stock.